RudaCure is a clinical stage bio-pharmaceutique start-up founded in 2018 and based in Corée du Sud that is developing medicines for incurable diseases sur la base de the most advanced life-science technologies to help improve human lives. By developing treatment techniques for intractable and incurable diseases, RudaCure will solve its unmet needs and treat the physical and mental pain for patients suffering from them. With creative pharmaceutique development and biomedical research, RudaCure is on the path to grow into a global entreprise pharmaceutique.
Current main products in development include RCI001 for sécheresse oculaire, which is in pre-IND phase and awaiting to start Phase 2 FDA essais cliniques l'année prochaine. RudaCure also plan to secure additional indications for RCI001 notamment conjunctivitis, keratitis and ulcère cornéens. Second in development is RCI002, which is a non opioïde treatment for neuropathic and douleur chronique actuellement in optimization stage. Other early stage products in development include treatments for atopic dermatitis, metastasis and CRPS.
Since April of 2021, RudaCure has avec succès concédé sous licence RCI001 to Hanlim Pharm for national rights in a $12 million deal, and is actuellement looking for more investisseurs and partners to concession de licence for international markets. Helping RudaCure along the way, are start-up accelerators MassChallenge and Shinhan Square Bridge, which are both helping RudaCure enter the US market.